Good afternoon, everyone. I now call this meeting to order.
Welcome to meeting number 21 of the House of Commons Standing Committee on Industry, Science and Technology. Pursuant to the order of reference of Saturday, April 11, the committee is meeting for the purpose of receiving evidence concerning matters related to the government's response to the COVID-19 pandemic.
Today's meeting is taking place by video conference, and the proceedings will be made available via the House of Commons website.
I would like to remind the members and witnesses to, before speaking, please wait until I recognize you by name. When you are ready to speak, please unmute your microphone and then return it to mute when you are finished speaking. When speaking, please speak slowly and clearly, so that the translators can do their work. As is my normal practice, I will hold up the yellow card when you have 30 seconds remaining, and I will hold up the red card when your time for questions has expired.
Now I would like to welcome our witnesses. From the Chemistry Industry Association of Canada, we have Madam Isabelle Des Chênes, executive vice-president.
From Groupe Robert Inc., we're joined by Jean-Robert Lessard, special adviser, public and government relations.
From Hoffman-La Roche Limited we have Logan Caragata, director, federal government affairs and policy, access division, and Fanny Sie, strategic healthcare partner, artificial intelligence and digital health. From the Montreal Port Authority we have Mr. Daniel Dagenais, vice-president, operations.
Each witness will present for seven minutes, followed by a round of questions.
With that, we will begin with Madam Des Chênes.
You have the floor for seven minutes.